C12Y 404/01001
Cystathionine gamma-lyase
Official title: Cystathionine gamma-lyase (4.4.1.1)
C12Y404/01001 (Cystathionine gamma-lyase) appears on 18 US grants and 33 published applications in this corpus.
Search patents in C12Y- Granted patents
- 18
- Published applications
- 33
- Assignees
- 17
- Inventors
- 55
- Latest grant
- 10 Dec 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2012 | 0 | 1 |
| 2013 | 0 | 0 |
| 2014 | 0 | 1 |
| 2015 | 0 | 3 |
| 2016 | 3 | 3 |
| 2017 | 1 | 2 |
| 2018 | 2 | 4 |
| 2019 | 2 | 3 |
| 2020 | 3 | 2 |
| 2021 | 1 | 3 |
| 2022 | 3 | 4 |
| 2023 | 0 | 2 |
| 2024 | 3 | 2 |
| 2025 | 0 | 2 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Engineered primate cystine/cysteine degrading enzymes for therapeutic uses10 Dec 2024US 12,163,168 B2Board of Regents, The University of Texas System
- Human-enzyme mediated depletion of homocysteine for treating patients with hyperhomocysteinemia and homocystinuria16 Jul 2024US 12,036,269 B2Board of Regents, The University of Texas System
- Treatment for methamphetamine cardiovascular disease30 Jan 2024US 11,883,426 B2Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
- Method of improving methyltransferase activity25 Oct 2022US 11,479,758 B2Danmarks Tekniske Universitet
- Antimalarial enzyme conjugates, kits containing same, and methods of producing and using same20 Sep 2022US 11,446,365 B2The Board of Regents of the University of Oklahoma
- Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof26 Feb 2026US 2026/0053924 A1
- Atp-dependent c-terminal modification of polypeptides13 Nov 2025US 2025/0346938 A1Wisconsin Alumni Research Foundation
- Cysteine prototrophy2 Oct 2025US 2025/0304911 A1Pfizer Inc.
- Treatment Of Homocystinuria And Hyperhomocysteinemia Using Cystathionine-Gamma-Lyase22 Feb 2024US 2024/0058429 A1Aeglea Bio Therapeutics, Inc.
- Treatment for methamphetamine cardiovascular disease8 Feb 2024US 2024/0041917 A1Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
Most cited
By later US patents
- Engineered primate L-methioninase for therapeutic purposes12US 9,481,877 B2Board of Regents, The University of Texas System · 2016
- Engineered primate L-methioninase for therapeutic purposes11US 9,624,484 B2Board of Regents, The University of Texas System · 2017
- Engineered primate L-methioninase for therapeutic purposes6US 10,233,438 B2Board of Regents, The University of Texas System · 2019
- Engineered primate cystine/cysteine degrading enzymes as antineogenic agents3US 10,363,311 B2Board of Regents, The University of Texas System · 2019
- Engineered primate cystine/cysteine degrading enzymes as antineogenic agents2US 10,716,856 B2Board of Regents, The University of Texas System · 2020